MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation

Reuters

2025/11/07

MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation

Mind Medicine (MindMed) Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581043641"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581043641\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581043641?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581043641","market":"fut","top_or_hot":-1,"title":"MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB熱門概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4gWQ53:1","article_id":"2581043641","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581043641","pubTimestamp":1762464542,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mind Medicine  Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder  and major depressive disorder . The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","BK4007":"制药"},"translate_title":"MindMed在新的公司演示中展示了后期管道进展和精神药物里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9},"content_text":"MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    \n\nMind Medicine (MindMed) Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}